Arterium Corporation has helped modernize two paediatric operating rooms in the Western-Ukrainian Specialized Children’s Medical Centre—new automatic doors have been installed there to increase compliance with European guidelines. 

On 23rd May 2019, Ukraine’s State Inspectorate for Quality Control of Medicines ordered to permanently withdraw from circulation in the country all fenspiride-containing medicinal products and cease production, sale, storage, and use thereof. Arterium Corporation’s Inspiron tablets and syrups have been affected too.

Arterium Corporation has launched a new product (substance) for hyperphosphatemia medication manufacturing – Sevelamer hydrochloride. The condition it helps treat is a potentially deadly electrolyte disorder characterized by the build-up of calcium and phosphorus in blood vessels, soft tissues, and heart valves.

In April, Arterium Corporation presented two new original products for the treatment of upper respiratory tract infections (URTI) – Narivent and Rinogermina, both nasal sprays.

Galychpharm undergone a routine GMP compliance inspection by the State Inspectorate for Quality Control of Medicines . The inspection was initiated by Galychpharm to extend the validity of its GMP certificate.

Arterium Corporation has presented a brochure under the title What You Should Know About Atrial Fibrillation. The publication is a part of What You Should Know – the company’s educational initiative launched to inform patients in a professional and popular manner about cardiac diseases, their causes, and prevention measures.